Surety Medicine 
Assessment of blood and vascular system abnormalities can identify PRP suitability challenges.  - US Army photo 

Assessment of blood and vascular system abnormalities can help identify
Personnel Reliability Program suitability challenges.                                 - US Army photo

March 2017 Surety Medicine Teleconference:

Peripheral Vascular Disease, DVT, and Anticoagulation - Assessing PRP Suitability

WEDNESDAY, 22 March 2017 will bring the next Surety Medicine Teleconference,
at 1 pm (1300 hrs) Eastern Time.  The topic for March will be “Peripheral Vascular Disease, DVT, and Anticoagulation—Assessing PRP Suitability.”  The physician presenter serves as a Competent Medical Authority at a U.S. Army chemical  weapons destruction installation medical support clinic.  Note that the March teleconference will take place on the fourth Wednesday of the month rather than
the third Wednesday; this change was necessary to prevent schedule conflicts.

To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:

usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil

______________________________________________________________

SCHEDULE OF SURETY MEDICINE
TELECONFERENCES FOR FY 2017

 Date           Topic                                                                                             

22 MAR 2017

Peripheral Vascular Disease, DVT, and Anticoagulation—
Assessing PRP Suitability

19 APR 2017

Abuse, Dependence and Substance Use Disorders: 
DSM-IV-TR vs. DSM-5

17 MAY 2017

Screening for Active TB or LTBI:  TB Skin tests vs. Alternatives

21 JUN 2017

Heat Stress Prevention and Management Issues
in the Surety Environment

19 JUL 2017

Syncopal Conditions:  Impacts on PRP Reliability

16 AUG 2017

Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA

20 SEP 2017

Obstructive Sleep Apnea:  Screening, Diagnosis,
Treatment and Compliance: 
The PRP Perspective

ALERT:  FDA Simplifies Rule for Anthrax PEP

FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS

The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at: 

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm  


ALERT:  Autoinjector Shelf Life Extension Program:  Current Information

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM:  Many expiration date extensions for autoinjector medications expire in 2017! 
Check any auto-injector medication stores you have.  Select the link
below for additional information from the FDA.

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019.  Complete FDA information related to the auto-injector shelf life extension program can be found at:  http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .  

Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors. 

_______________________________________________________________

 

Related programs and contacts